Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00072358
First received: November 4, 2003
Last updated: October 9, 2015
Last verified: October 2015